

ABSTRACT

The present invention relates to new IL-11 muteins of which site I hydrophobicity has been increased. These muteins act as IL-11 agonist or hyperagonist, and are notably useful as anti-thrombocytopenia agents, and as agents improving the resistance of an organism to the deleterious *in vivo* effects induced by radiation or chemotherapy during the treatment of cancer or for the preparation of patient to transplantation.